Literature DB >> 3865500

Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications.

P Knudsen, L B Hansen, N E Larsen.   

Abstract

Ten schizophrenic inpatients were each treated with perphenazine enanthate (PE) and perphenazine decanoate (PD). Following a cross-over study design it was possible to evaluate differences in plasma profiles between the two preparations, and to relate these to encountered side effects. All patients had previously been receiving neuroleptic treatment and had been diagnosed according to DSM-III. The dosage and intervals between injections were on an individual basis. The results indicate that at all dosage levels, the decanoate preparation showed significantly lower peak plasma concentrations of perphenazine. Extrapyramidal side effects and sedation were also less pronounced after the administration of PD. The more even and flat plasma concentrations obtained with PD, may facilitate plasma monitored therapy by using minimum concentration values.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865500     DOI: 10.1111/j.1600-0447.1985.tb08536.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  4 in total

Review 1.  Depot pipotiazine palmitate and undecylenate for schizophrenia.

Authors:  M Dinesh; A David; S N Quraishi
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 2.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Depot perphenazine decanoate and enanthate for schizophrenia.

Authors:  A David; S Quraishi; J Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

Review 4.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.